Document Detail


Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure.
MedLine Citation:
PMID:  20807184     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: The heart failure and cardiorenal syndromes are major public health hazards, affecting one in five persons during their lifetime. Alternatives to traditional loop-diuretics, including vasopressin and adenosine A(1) receptor antagonists are now in development.
AREAS COVERED IN THIS REVIEW: The pathophysiologic rationale for the use of tonapofylline, an intravenous and oral adenosine A(1) receptor antagonist, in patients with heart failure and/or the cardiorenal syndrome are reviewed. A comprehensive review of published literature describing its medicinal chemistry, pharmacokinetics, efficacy, safety and tolerability are provided. We searched the Medline/PubMed and Embase databases for the terms 'BG9928', 'tonapofylline', 'Adentri', 'adenosine', 'heart failure', 'renal failure' and 'cardiorenal syndrome' from 1 January 1992 to the present. References from pertinent manuscripts were also reviewed for additional relevant content.
WHAT THE READER WILL GAIN: The reader will better appreciate the potential role of tonapofylline in patients with heart failure and/or the cardiorenal syndrome. Additionally, the reader will gain an understanding of the current state of drug development and the rationale for the need for continued research.
TAKE HOME MESSAGE: Tonapofylline promotes natriuresis and diuresis, and may preserve glomerular filtration rate in patients with heart failure. Additionally, pilot data indicate that tonapofylline may be renoprotective in the setting of concomitant treatment with a loop-diuretic. Adverse effects were generally mild.
Authors:
Christopher R Ensor; Stuart D Russell
Related Documents :
2146334 - Rett's syndrome: a case study.
15850814 - Computer vision syndrome: a review.
15171814 - Immunological features of neurological paraneoplastic syndromes.
2487484 - Travellers in five worlds: adolescents with ganser's syndrome.
24269454 - Paradoxical cessation in a case of charles bonnet syndrome.
2173474 - Polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudo-obstruction...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-10     Completed Date:  2010-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2405-15     Citation Subset:  IM    
Affiliation:
The Johns Hopkins Hospital, Comprehensive Transplant Center, Department of Pharmacy, 600 North Wolfe St., Carnegie 180, Baltimore, MD 21287-6180, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine A1 Receptor Antagonists / pharmacology,  therapeutic use*
Cardiovascular Agents / pharmacology,  therapeutic use*
Heart Failure / drug therapy*
Humans
Xanthines / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Adenosine A1 Receptor Antagonists; 0/BG 9928; 0/Cardiovascular Agents; 0/Xanthines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of pressure mapping for seating posture characterisation in children with cerebral palsy.
Next Document:  Conformational diseases: structural studies of aggregation of polyglutamine proteins.